ZNF830

Summary

ZNF830 (zinc finger protein 830, HGNC:28291) is a protein-coding gene on chromosome 17q12, encoding Zinc finger protein 830 (Q96NB3). May play a role in pre-mRNA splicing as component of the spliceosome. It is a common-essential gene (DepMap: required in 99.4% of cancer cell lines).

Predicted to enable nucleic acid binding activity and zinc ion binding activity. Predicted to be involved in several processes, including mitotic DNA integrity checkpoint signaling; nuclear DNA replication; and preantral ovarian follicle growth. Predicted to act upstream of or within several processes, including blastocyst growth; chromosome organization; and intestinal epithelial structure maintenance. Predicted to be located in nucleoplasm. Predicted to be part of spliceosomal complex. Predicted to be active in nucleus.

Source: NCBI Gene 91603 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 39 total
• Cancer dependency (DepMap): dependent in 99.4% of screened cell lines (common-essential)
• MANE Select transcript: NM_052857

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28291
Approved symbol	ZNF830
Name	zinc finger protein 830
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	MGC20398, OMCG1
Ensembl gene	ENSG00000198783
Ensembl biotype	protein_coding
Entrez	91603

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 nonsense_mediated_decay

ENST00000361952, ENST00000578339

RefSeq mRNA: 1 — MANE Select: NM_052857 NM_052857

CCDS: CCDS32618

Canonical transcript exons

ENST00000361952 — 1 exons

Exon	Start	End
ENSE00001106040	34961540	34963777

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 95.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.1583 / max 139.9218, expressed in 1727 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160324	7.1583	1727

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	95.81	gold quality
kidney epithelium	UBERON:0004819	94.02	gold quality
epithelial cell of pancreas	CL:0000083	93.75	gold quality
upper arm skin	UBERON:0004263	92.76	gold quality
left ventricle myocardium	UBERON:0006566	92.70	gold quality
cardiac muscle of right atrium	UBERON:0003379	92.59	gold quality
epithelium of nasopharynx	UBERON:0001951	92.43	gold quality
parotid gland	UBERON:0001831	91.83	gold quality
thymus	UBERON:0002370	91.82	gold quality
medial globus pallidus	UBERON:0002477	91.06	gold quality
germinal epithelium of ovary	UBERON:0001304	90.69	gold quality
tendon	UBERON:0000043	90.58	gold quality
pylorus	UBERON:0001166	89.88	gold quality
globus pallidus	UBERON:0001875	89.77	gold quality
cerebellar vermis	UBERON:0004720	89.65	gold quality
cardia of stomach	UBERON:0001162	89.30	gold quality
amniotic fluid	UBERON:0000173	88.77	gold quality
palpebral conjunctiva	UBERON:0001812	88.75	gold quality
tibialis anterior	UBERON:0001385	88.64	gold quality
pericardium	UBERON:0002407	88.64	gold quality
calcaneal tendon	UBERON:0003701	88.60	gold quality
layer of synovial tissue	UBERON:0007616	88.25	gold quality
mammalian vulva	UBERON:0000997	87.87	gold quality
urethra	UBERON:0000057	87.79	gold quality
decidua	UBERON:0002450	87.76	gold quality
deltoid	UBERON:0001476	87.74	gold quality
trabecular bone tissue	UBERON:0002483	87.67	gold quality
ileal mucosa	UBERON:0000331	87.60	gold quality
dorsal root ganglion	UBERON:0000044	87.13	gold quality
granulocyte	CL:0000094	87.07	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.78
E-GEOD-110499	no	397.63
E-CURD-10	no	246.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting ZNF830, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-573	99.55	67.44	955
HSA-MIR-5683	99.36	68.59	2083

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.4% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 1)

• ZNF830 mediates cancer chemoresistance through promoting homologous recombination repair. (PMID:29244158)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp830	ENSMUSG00000046010
rattus_norvegicus	Zfp830	ENSRNOG00000073735
drosophila_melanogaster	CG11839	FBGN0039271
caenorhabditis_elegans		WBGENE00011411

Protein

Protein identifiers

Zinc finger protein 830 — Q96NB3 (reviewed: Q96NB3)

Alternative names: Coiled-coil domain-containing protein 16

All UniProt accessions (2): Q96NB3, J3QQQ3

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in pre-mRNA splicing as component of the spliceosome. Acts as an important regulator of the cell cycle that participates in the maintenance of genome integrity. During cell cycle progression in embryonic fibroblast, prevents replication fork collapse, double-strand break formation and cell cycle checkpoint activation. Controls mitotic cell cycle progression and cell survival in rapidly proliferating intestinal epithelium and embryonic stem cells. During the embryo preimplantation, controls different aspects of M phase. During early oocyte growth, plays a role in oocyte survival by preventing chromosomal breaks formation, activation of TP63 and reduction of transcription.

Subunit / interactions. Component of the XAB2 complex, a multimeric protein complex composed of XAB2, PRPF19, AQR, ZNF830, ISY1, and PPIE; this complex binds preferentially to RNA. Interacts with XAB2. Identified in a pentameric intron-binding (IB) complex composed of AQR, XAB2, ISY1, ZNF830 and PPIE that is incorporated into the spliceosome as a preassembled complex. The IB complex does not contain PRPF19.

Subcellular location. Nucleus. Chromosome. Nucleus speckle.

Post-translational modifications. Phosphorylated in response to DNA damage by the cell cycle checkpoint kinases ATR/ATM.

RefSeq proteins (1): NP_443089* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003604	Matrin/U1-like-C_Znf_C2H2	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR040050	ZNF830-like	Family
IPR059039	ZNF380_CC	Domain

Pfam: PF12874, PF23406

UniProt features (19 total): sequence variant 5, modified residue 4, compositionally biased region 4, region of interest 2, initiator methionine 1, chain 1, zinc finger region 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96NB3-F1	66.50	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 2, 225, 351, 362

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-6781823	Formation of TC-NER Pre-Incision Complex
R-HSA-6781827	Transcription-Coupled Nucleotide Excision Repair (TC-NER)
R-HSA-6782135	Dual incision in TC-NER
R-HSA-6782210	Gap-filling DNA repair synthesis and ligation in TC-NER
R-HSA-72163	mRNA Splicing - Major Pathway

MSigDB gene sets: 155 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, GOBP_CELL_CYCLE_DNA_REPLICATION, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_GROWTH, GOBP_OOGENESIS, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, GOBP_MITOTIC_G2_M_TRANSITION_CHECKPOINT, GOBP_REGULATION_OF_CELL_CYCLE_G2_M_PHASE_TRANSITION, GOBP_OVARIAN_FOLLICLE_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE

GO Biological Process (14): ovarian follicle development (GO:0001541), preantral ovarian follicle growth (GO:0001546), blastocyst growth (GO:0001832), RNA processing (GO:0006396), mRNA processing (GO:0006397), RNA splicing (GO:0008380), nuclear DNA replication (GO:0033260), mitotic DNA replication checkpoint signaling (GO:0033314), negative regulation of apoptotic process (GO:0043066), mitotic DNA damage checkpoint signaling (GO:0044773), chromosome organization (GO:0051276), cell division (GO:0051301), intestinal epithelial structure maintenance (GO:0060729), mitotic cell cycle (GO:0000278)

GO Molecular Function (4): nucleic acid binding (GO:0003676), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), chromosome (GO:0005694), nuclear speck (GO:0016607)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Transcription-Coupled Nucleotide Excision Repair (TC-NER)	3
Nucleotide Excision Repair	1
mRNA Splicing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
developmental growth	2
RNA processing	2
cell cycle	2
mitotic cell cycle	2
mitotic DNA integrity checkpoint signaling	2
binding	2
female gonad development	1
anatomical structure development	1
ovarian follicle development	1
ovulation cycle process	1
multi-layer follicle stage	1
blastocyst development	1
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
mRNA metabolic process	1
nucleus	1
cell cycle DNA replication	1
DNA replication checkpoint signaling	1
mitotic G2/M transition checkpoint	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
DNA damage checkpoint signaling	1
organelle organization	1
cellular process	1
maintenance of gastrointestinal epithelium	1
mitotic nuclear division	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
intracellular membraneless organelle	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

704 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF830	PPIE	Q9UNP9	926
ZNF830	PRPF19	Q9UMS4	874
ZNF830	CRNKL1	Q9BZJ0	792
ZNF830	XAB2	Q9HCS7	785
ZNF830	AQR	O60306	753
ZNF830	PRCC	Q92733	696
ZNF830	KANSL2	Q9H9L4	665
ZNF830	PIM2	Q9P1W9	646
ZNF830	CDC5L	Q99459	593
ZNF830	SNW1	Q13573	498
ZNF830	RBBP8	Q99708	494
ZNF830	ZNF281	Q9Y2X9	478
ZNF830	ASCC2	Q9H1I8	474
ZNF830	CFAP221	Q4G0U5	471
ZNF830	FKBP6	O75344	465

IntAct

69 interactions, top by confidence:

A	B	Type	Score
BCL2L1	BCL2L11	psi-mi:“MI:0914”(association)	0.870
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
PPIE	AQR	psi-mi:“MI:0914”(association)	0.810
PRPF19	PLRG1	psi-mi:“MI:0914”(association)	0.770
AQR	ZNF830	psi-mi:“MI:0407”(direct interaction)	0.760
AQR	ZNF830	psi-mi:“MI:0915”(physical association)	0.760
AQR	ZNF830	psi-mi:“MI:0914”(association)	0.760
ISY1	AQR	psi-mi:“MI:0914”(association)	0.740
SNW1	AQR	psi-mi:“MI:0914”(association)	0.650
SNW1	ZNF830	psi-mi:“MI:0915”(physical association)	0.630
ZNF830	PPIL2	psi-mi:“MI:0915”(physical association)	0.630
ZNF830	SNW1	psi-mi:“MI:0915”(physical association)	0.630
PPIL2	ZNF830	psi-mi:“MI:0915”(physical association)	0.630
APPL1	ZNF830	psi-mi:“MI:0915”(physical association)	0.590
SESTD1	ZNF830	psi-mi:“MI:0915”(physical association)	0.560
SNRPE	PRMT5	psi-mi:“MI:0914”(association)	0.530
PRPF19	STRN	psi-mi:“MI:0914”(association)	0.530
SNRPE	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
PRPF8	ZNF830	psi-mi:“MI:0915”(physical association)	0.510

BioGRID (131): ZNF830 (Affinity Capture-MS), ZNF830 (Co-fractionation), ZNF830 (Co-fractionation), ZNF830 (Co-fractionation), ZNF830 (Affinity Capture-MS), ZNF830 (Affinity Capture-MS), AQR (Affinity Capture-MS), XAB2 (Affinity Capture-MS), ISY1 (Affinity Capture-MS), PPIE (Affinity Capture-MS), PPIL2 (Affinity Capture-MS), ZNF830 (Affinity Capture-MS), ZNF830 (Affinity Capture-MS), ZNF830 (Affinity Capture-MS), ZNF830 (Affinity Capture-MS)

ESM2 similar proteins: A4PB26, D3ZTQ1, G1SW77, O16053, O88271, Q12872, Q32LE2, Q3MHS2, Q3U155, Q3USH5, Q4ADK4, Q4ADK7, Q4VAA2, Q5M8L3, Q5PQP2, Q5PQS7, Q5RKH3, Q5VSY0, Q5XHI2, Q5XIG5, Q5XIM5, Q5ZLH9, Q60FC2, Q63ZM9, Q6AXS5, Q6DIS2, Q6DJ13, Q6GNQ4, Q6NWC9, Q6PFK1, Q75UQ2, Q7T370, Q7ZYA6, Q8HXY9, Q8K039, Q8MMC4, Q8NC51, Q8R1N0, Q92733, Q96NB3

Diamond homologs: Q3MHS2, Q63ZM9, Q6DJ13, Q6P0I6, Q8R1N0, Q96NB3, Q9M8S7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 55 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Splicing - Minor Pathway	6	29.9×	1e-06
mRNA Splicing - Major Pathway	21	25.5×	8e-23
mRNA Splicing	10	24.4×	4e-10
Processing of Capped Intron-Containing Pre-mRNA	13	23.7×	4e-13
mRNA Polyadenylation	10	19.5×	3e-09
CHD1 and CHD2 subfamily	8	19.3×	3e-07
Dengue Virus-Host Interactions	18	18.3×	1e-16
Metabolism of RNA	12	11.1×	2e-08

GO biological processes:

GO term	Partners	Fold	FDR
U2-type prespliceosome assembly	6	76.4×	2e-08
mRNA splicing, via spliceosome	22	41.1×	3e-28
RNA splicing	7	12.6×	1e-04
mRNA processing	7	11.2×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

51 predictions. Top by Δscore:

Variant	Effect	Δscore
17:34962599:G:GT	donor_gain	0.8800
17:34962629:G:GT	donor_gain	0.7200
17:34962641:G:GT	donor_gain	0.7000
17:34962656:G:GT	donor_gain	0.5300
17:34962211:CAAGG:C	acceptor_gain	0.5100
17:34962666:TGA:T	donor_gain	0.4400
17:34962210:CCAAG:C	acceptor_gain	0.4300
17:34962632:G:T	donor_gain	0.4300
17:34962212:AAGGC:A	acceptor_gain	0.4100
17:34961938:AC:A	donor_gain	0.3800
17:34962133:C:T	donor_gain	0.3800
17:34962209:CCCAA:C	acceptor_gain	0.3800
17:34962161:G:GT	donor_gain	0.3600
17:34962204:ATCCT:A	acceptor_gain	0.3500
17:34962213:AGG:A	acceptor_gain	0.3500
17:34962624:A:G	donor_gain	0.3400
17:34962161:G:T	donor_gain	0.3200
17:34962208:TCCCA:T	acceptor_gain	0.3200
17:34962632:G:GT	donor_gain	0.3100
17:34961983:A:T	donor_gain	0.3000
17:34962205:TCCTC:T	acceptor_gain	0.3000
17:34962206:CCTCC:C	acceptor_gain	0.3000
17:34962207:CTCCC:C	acceptor_gain	0.3000
17:34962668:A:AG	donor_gain	0.2700
17:34961931:CTCAG:C	donor_loss	0.2600
17:34961932:TCAG:T	donor_loss	0.2600
17:34961933:CAGGT:C	donor_loss	0.2600
17:34961934:AG:A	donor_loss	0.2600
17:34961935:GGT:G	donor_loss	0.2600
17:34961936:GTACA:G	donor_loss	0.2600

AlphaMissense

2445 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:34962314:T:C	F250L	1.000
17:34962316:T:A	F250L	1.000
17:34962316:T:G	F250L	1.000
17:34962395:T:C	F277L	1.000
17:34962396:T:C	F277S	1.000
17:34962397:C:A	F277L	1.000
17:34962397:C:G	F277L	1.000
17:34962498:A:C	Q311P	1.000
17:34962661:G:C	W365C	1.000
17:34962661:G:T	W365C	1.000
17:34961723:T:C	C53R	0.999
17:34961745:T:A	V60D	0.999
17:34961762:T:A	W66R	0.999
17:34961762:T:C	W66R	0.999
17:34961764:G:C	W66C	0.999
17:34961764:G:T	W66C	0.999
17:34962303:T:C	L246S	0.999
17:34962315:T:C	F250S	0.999
17:34962317:T:C	F251L	0.999
17:34962318:T:G	F251C	0.999
17:34962319:T:A	F251L	0.999
17:34962319:T:G	F251L	0.999
17:34962386:T:A	W274R	0.999
17:34962386:T:C	W274R	0.999
17:34962388:G:C	W274C	0.999
17:34962388:G:T	W274C	0.999
17:34962396:T:G	F277C	0.999
17:34962404:G:C	A280P	0.999
17:34962434:G:C	A290P	0.999
17:34962443:G:C	A293P	0.999

dbSNP variants (sampled 300 via entrez): RS1001361386 (17:34963770 T>C), RS1002989528 (17:34962284 G>A), RS1003114732 (17:34962842 G>A,T), RS1003321442 (17:34961173 C>A,T), RS1003378809 (17:34960984 C>G), RS1005432992 (17:34961452 C>G,T), RS1005539603 (17:34963444 T>C), RS1005801525 (17:34961510 G>A,T), RS1007066420 (17:34960348 C>A,T), RS1007163112 (17:34959939 A>C), RS1007521674 (17:34960161 C>A,T), RS1008948409 (17:34963078 T>C), RS1009877886 (17:34964053 C>T), RS1010059103 (17:34963160 A>G), RS1011345508 (17:34961926 G>C,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003542_132	Night sleep phenotypes	2.000000e-07
GCST003542_133	Night sleep phenotypes	4.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
potassium chromate(VI)	increases expression, affects cotreatment	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Doxorubicin	decreases phosphorylation, affects phosphorylation, affects response to substance	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Potassium Dichromate	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
Vincristine	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Vitamin K 3	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.